Meet us at the 2nd annual Spatial Biology for Drug Development Summit. We’re excited to be a Program Partner for the Spatial Biology for Drug Development Summit, returning to Boston for a 2nd year, October 22-24. This year, we’ll dive into the latest in spatial omics...
Meet with us in Boston for World CB & CDx.We’re thrilled to be a Spotlight Partner for the 14th World Clinical Biomarkers and Companion Diagnostics Summit. Join us there to exchange insights with biotech and pharma leaders, researchers, and scientists and to discuss...
Meet with us at booth #25. As a Gold Sponsor for the third annual Spatial Biology East Coast Congress in Boston, we hope you’ll join our experts and over 350 other industry leaders to discuss the transforming field of spatial biology. Examine how spatial biology can...
Meet with us at booth #37085. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 2024 ASCO® Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions Biomarker...
Are you attending the 2024 ASGCT Annual Meeting? With field-leading keynotes, 200+ scientific sessions, over 7,000 researchers in attendance, and an expanded exhibit hall, the 27th American Society of Gene and Cell Therapy Annual Meeting is the nexus for gene and cell...
Meet with us at the AACR Annual Meeting 2024 to learn about our spatial biology solutions. Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Dr. Henderson is Vice President of Computational & Imaging Sciences at Flagship. With a passion for innovative technology and solving problems for clients, Dr. Henderson not only inspires his team but also pushes the boundaries of what’s possible in our industry....
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...
PUBLICATIONS/POSTERS
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...